{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-121069","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.439389+00:00","generated_at":"2026-05-30T05:25:23.149228+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Beam Therapeutics Q3 net loss $96.7M; cash $925.8M; BEAM-101 enrollment at 35 patients","bullets":["Net loss $96.7M ($1.17/share) vs $96.1M ($1.22) Q3 2023; R&D $94.3M, G&A $26.5M.","Cash, equivalents, and marketable securities $925.8M as of Sep 30, 2024; runway into 2027.","BEACON trial of BEAM-101: 35 patients enrolled, 8 dosed in sickle cell disease; ASH data Dec 2024.","First cohort dosing complete for BEAM-302 in alpha-1 antitrypsin deficiency; initial data expected 2025.","ESCAPE platform (BEAM-103/104) nominated for development in SCD and beta-thalassemia."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-121069","json":"https://secwatch.observer/filing/0000950170-24-121069.json","markdown":"https://secwatch.observer/filing/0000950170-24-121069.md","text":"https://secwatch.observer/filing/0000950170-24-121069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024121069/0000950170-24-121069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024121069/beam-20241105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:25:23.149228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}